GlassScriptPhysician profile
Ehab R Morsi
NPI 1790781383
$3,077.49
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $130 · 2021: $332 · 2022: $520 · 2023: $696 · 2024: $682 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $521.67 | 2019-2025 | |
| Tris Pharma INC | $439.15 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $318.13 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $298.31 | 2022-2024 | Azstarys |
| Glaxosmithkline, LLC. | $285.31 | 2020-2025 | Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $205.12 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi Pasteur INC. | $197.61 | 2022-2025 | |
| Cranial Technologies, INC | $174.11 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $134.91 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $41.55 | 2024 | Flumist Quadrivalent |
| Kaleo, INC. | $39.47 | 2023 | Auvi-Q |
| Alk-Abello, INC | $36.15 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $35.57 | 2025 | Jornay Pm |
| Genentech USA, INC. | $35.23 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.29 | 2021 | |
| Ucb, INC. | $26.61 | 2024 | Nayzilam |
| Alexion Pharmaceuticals, INC. | $26.36 | 2025 | Koselugo |
| Aimmune Therapeutics, INC. | $24.75 | 2023 | |
| Shire North American Group INC | $23.50 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.93 | 2024 | Ycanth |
| Biomarin Pharmaceutical INC. | $19.72 | 2025 | Voxzogo 1.2mg |
| Sobi, INC | $15.90 | 2019 | |
| Seqirus USA INC | $14.31 | 2023 | Flucelvax Quadrivalent |
| Adlon Therapeutics L.P. | $12.50 | 2021 | |
| Dermira, INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Morsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.